Pharmacokinetics for regulatory risk analysis: the case of trichloroethylene

Regul Toxicol Pharmacol. 1988 Dec;8(4):447-66. doi: 10.1016/0273-2300(88)90045-1.

Abstract

Physiologically based pharmacokinetic (PBPK) models describing the uptake, metabolism, and excretion of volatile organic compounds (VOCs) are now proposed for use in regulatory health-risk assessment. A steady-state analysis of one such model is shown to provide simple, convenient predicted relationships between an applied dose and the corresponding toxicologically effective, metabolized dose for certain VOCs like trichloroethylene (TCE). A version of this PBPK model was fit to data on human metabolism of TCE to urinary metabolites in chronically exposed workers, yielding a direct estimate of PBPK parameters governing human capacity to metabolize TCE. It is shown that this estimate is consistent with others based on experimental studies of TCE metabolism in humans exposed to TCE by inhalation for short periods. These results are applied to human cancer-risk assessment using rodent bioassay data on TCE-induced tumorigenesis.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Carcinogenicity Tests
  • Humans
  • Risk Factors
  • Trichloroethylene / pharmacokinetics*
  • Trichloroethylene / toxicity

Substances

  • Trichloroethylene